Preprint Article Version 1 This version is not peer-reviewed

Identification of Biomarker Signatures and Candidate Drugs in Non-Small Cell Lung Cancer

Version 1 : Received: 30 June 2019 / Approved: 3 July 2019 / Online: 3 July 2019 (08:54:37 CEST)

How to cite: Rownaq, A.; Mosharaf, M.P.; Islam, S.M.S.; Mollah, M.N.H. Identification of Biomarker Signatures and Candidate Drugs in Non-Small Cell Lung Cancer. Preprints 2019, 2019070051 (doi: 10.20944/preprints201907.0051.v1). Rownaq, A.; Mosharaf, M.P.; Islam, S.M.S.; Mollah, M.N.H. Identification of Biomarker Signatures and Candidate Drugs in Non-Small Cell Lung Cancer. Preprints 2019, 2019070051 (doi: 10.20944/preprints201907.0051.v1).

Abstract

Lung cancer is one of the most important health risks worldwide for human. Non-small cell lung cancer (NSCLC) is the most common cause of premature death from malignant disease. This study provides in-depth insights from systems biology analyses to identify molecular to inform systemic drug targeting in NSCLC. Gene expression profiles from non small cell lung cancer were analyzed with genome-scale biomolecular networks (I,e., protein-protein interaction, transcriptional and post transcriptional regulatory networks). The aim of the study was to determine the pathways and expression profile of the genes to discover molecular signature at RNA and protein levels which could serve as potential drug targets for therapeutics innovation and the identification of novel targets. Eight proteins, six TFs and seven miRNAs came into prominence as potential drug targets. The differential expression profiles of these reporter biomolecules were cross-validated by independent RNA-Seq and miRNA-Seq. Risk discrimination performance of the reporter biomolecules NPR3, JUN, PPARG, TP53, CKMT1A, SP3 and TFAP2A were also evaluated. Total 213 drugs and 7 proteins were found for non small cell lung cancer through dgidb. Among these identified drugs seven drugs such as- Gemcitabine, Carboplatin, paclitaxel, Docetaxel, Crizotinib, Bevacizumab and Gemcitabine is used for NSCLC which is approved by National Cancer Institute. The molecular signatures and repurposed drugs presented here permit further attention for experimental studies which are offer significant potential as biomarkers and candidate therapeutics for precision medicine approaches to clinical management of NSCLC.

Subject Areas

lung cancer; molecular signature; molecular pathway; differentially expressed genes; protein-protein interaction; reporter biomolecules and bioinformatics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.